The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Salmeterol and Fluticasone Propionate and Survival in Chronic Obstructive Pulmonary Disease
Open accessAbstract
BACKGROUND: Long-acting beta-agonists and inhaled corticosteroids are used to treat chronic obstructive pulmonary disease (COPD), but their effect on survival is unknown. METHODS: We conducted a randomized, double-blind trial comparing salmeterol at a dose of 50 microg plus fluticasone propionate at a dose of 500 microg twice daily (combination regimen), administered with a single inhaler, with placebo, salmeterol alone, or fluticasone propionate alone for a period of 3 years. The primary outcome was death from any cause for the comparison between the combination regimen and placebo; the frequency of exacerbations, health status, and spirometric values were also assessed. RESULTS: Of 6112 patients in the efficacy population, 875 died within 3 years after the start of the study treatment. All-cause mortality rates were 12.6% in the combination-therapy group, 15.2% in the placebo group, 13.5% in the salmeterol group, and 16.0% in the fluticasone group. The hazard ratio for death in the combination-therapy group, as compared with the placebo group, was 0.825 (95% confidence interval [CI], 0.681 to 1.002; P=0.052, adjusted for the interim analyses), corresponding to a difference of 2.6 percentage points or a reduction in the risk of death of 17.5%. The mortality rate for salmeterol alone or fluticasone propionate alone did not differ significantly from that for placebo. As compared with placebo, the combination regimen reduced the annual rate of exacerbations from 1.13 to 0.85 and improved health status and spirometric values (P<0.001 for all comparisons with placebo). There was no difference in the incidence of ocular or bone side effects. The probability of having pneumonia reported as an adverse event was higher among patients receiving medications containing fluticasone propionate (19.6% in the combination-therapy group and 18.3% in the fluticasone group) than in the placebo group (12.3%, P<0.001 for comparisons between these treatments and placebo). CONCLUSIONS: The reduction in death from all causes among patients with COPD in the combination-therapy group did not reach the predetermined level of statistical significance. There were significant benefits in all other outcomes among these patients. (ClinicalTrials.gov number, NCT00268216 [ClinicalTrials.gov].).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lung volumes and forced ventilatory flows
Quanjer, P. H., Tammeling, G. J., Cotes, J. E., Pedersen, O. F., Peslin, R., & Yernault, J.-C. (1993) · European Respiratory Journal · doi:10.1183/09041950.005s1693 · Cited by 5,318
(1993) · PubMed · Cited by 3,827
The Nature of Small-Airway Obstruction in Chronic Obstructive Pulmonary Disease
Hogg, J. C., Chu, F., Utokaparch, S., Woods, R., Elliott, W. M., Buzatu, L., Cherniack, R. M., Rogers, R. M., Sciurba, F. C., Coxson, H. O., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032158 · Cited by 3,782
NOCTURNAL OXYGEN THERAPY TRIAL GROUP* (1980) · Annals of Internal Medicine · doi:10.7326/0003-4819-93-3-391 · Cited by 2,218
A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema
(2003) · New England Journal of Medicine · doi:10.1056/nejmoa030287 · Cited by 2,071
Chronic obstructive pulmonary disease: current burden and future projections
Lopez, A. D., Shibuya, K., Rao, C., Mathers, C. D., Hansell, A. L., Held, L. S., Schmid, V., & Buist, S. (2006) · European Respiratory Journal · doi:10.1183/09031936.06.00025805 · Cited by 1,335
Effect of Statins on Risk of Coronary Disease: A Meta-analysis of Randomized Controlled Trials
LaRosa, J. C., He, J., & Vupputuri, S. (1999) · JAMA · doi:10.1001/jama.282.24.2340 · Cited by 1,246
The Effects of a Smoking Cessation Intervention on 14.5-Year Mortality: A Randomized Clinical Trial
Anthonisen, N. R., Skeans, M. A., Wise, R. A., Manfreda, J., Kanner, R. E., Connett, J. E., & for the Lung Health Study Research Group* (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-4-200502150-00005 · Cited by 1,237
Cited by
Items 101–146 of 146
Lung Cancer in Patients with Chronic Obstructive Pulmonary Disease: Incidence and Predicting Factors
de Torres, J. P., Marín, J. M., Casanova, C., Cote, C., Carrizo, S., Cordoba-Lanus, E., Baz-Dávila, R., Zulueta, J. J., Aguirre-Jaime, A., Saetta, M., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201103-0430oc · Cited by 304
Self-citationBeck, I. M. E., Vanden Berghe, W., Vermeulen, L., Yamamoto, K. R., Haegeman, G., & De Bosscher, K. (2009) · Endocrine Reviews · doi:10.1210/er.2009-0013 · Cited by 298
Decramer, M., Rennard, S., Troosters, T., Mapel, D. W., Giardino, N., Mannino, D., Wouters, E., Sethi, S., & Cooper, C. B. (2008) · COPD: Journal of Chronic Obstructive Pulmonary Disease · doi:10.1080/15412550802237531 · Cited by 295
Dicker, A. J., Crichton, M. L., Pumphrey, E. G., Cassidy, A. J., Suarez-Cuartin, G., Sibila, O., Furrie, E., Fong, C. J., Ibrahim, W., Brady, G., et al. (2018) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2017.04.022 · Cited by 295
McAllister, D. A., Maclay, J. D., Mills, N. L., Mair, G., Miller, J., Anderson, D., Newby, D. E., Murchison, J. T., & MacNee, W. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200707-1080oc · Cited by 292
Chronic obstructive pulmonary disease and comorbidities
Decramer, M., & Janssens, W. (2013) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(12)70060-7 · Cited by 291
Prevention of Acute Exacerbations of COPD
Criner, G. J., Bourbeau, J., Diekemper, R. L., Ouellette, D. R., Goodridge, D., Hernandez, P., Curren, K., Balter, M. S., Bhutani, M., Camp, P. G., et al. (2015) · Chest · doi:10.1378/chest.14-1676 · Cited by 288
Self-citationBusacker, A., Newell, J. D., Keefe, T., Hoffman, E. A., Granroth, J. C., Castro, M., Fain, S., & Wenzel, S. (2009) · Chest · doi:10.1378/chest.08-0049 · Cited by 287
Woods, B. S., Hawkins, N., & Scott, D. A. (2010) · BMC Medical Research Methodology · doi:10.1186/1471-2288-10-54 · Cited by 286
Outpatient pulmonary rehabilitation following acute exacerbations of COPD
Seymour, J. M., Moore, L., Jolley, C. J., Ward, K., Creasey, J., Steier, J. S., Yung, B., Man, W. D. C., Hart, N., Polkey, M. I., et al. (2010) · Thorax · doi:10.1136/thx.2009.124164 · Cited by 282
Celli, B., Decramer, M., Kesten, S., Liu, D., Mehra, S., & Tashkin, D. P. (2009) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200906-0876oc · Cited by 281
Self-citationCOPD-related morbidity and mortality after smoking cessation: status of the evidence
Godtfredsen, N. S., Lam, T. H., Hansel, T. T., Leon, M. E., Gray, N., Dresler, C., Burns, D. M., Prescott, E., & Vestbo, J. (2008) · European Respiratory Journal · doi:10.1183/09031936.00160007 · Cited by 279
Self-citationBarnes, P. J. (2010) · Pharmaceuticals · doi:10.3390/ph3030514 · Cited by 277
Palliative and end-of-life care for patients with severe COPD
Curtis, J. R. (2008) · European Respiratory Journal · doi:10.1183/09031936.00126107 · Cited by 275
Nannini, L. J., Poole, P., Milan, S. J., Holmes, R., & Normansell, R. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003794.pub4 · Cited by 274
The Primary Outcome Fails — What Next?
Pocock, S. J., & Stone, G. W. (2016) · New England Journal of Medicine · doi:10.1056/nejmra1510064 · Cited by 274
Molimard, M., Raherison, C., Lignot, S., Balestra, A., Lamarque, S., Chartier, A., Droz-Perroteau, C., Lassalle, R., Moore, N., & Girodet, P.-O. (2017) · European Respiratory Journal · doi:10.1183/13993003.01794-2016 · Cited by 273
Martinez, F. J., Rabe, K. F., Ferguson, G. T., Wedzicha, J. A., Singh, D., Wang, C., Rossman, K., St. Rose, E., Trivedi, R., Ballal, S., et al. (2021) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202006-2618oc · Cited by 269
Self-citationAgustí, A. (2007) · Proceedings of the American Thoracic Society · doi:10.1513/pats.200701-004fm · Cited by 265
Prevalence and Progression of Osteoporosis in Patients With COPD
Ferguson, G. T., Calverley, P. M. A., Anderson, J. A., Jenkins, C. R., Jones, P. W., Willits, L. R., Yates, J. C., Vestbo, J., & Celli, B. (2009) · Chest · doi:10.1378/chest.08-3016 · Cited by 265
Self-citationNannini, L. J., Lasserson, T. J., & Poole, P. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006829.pub2 · Cited by 264
Clunes, L. A., Davies, C. M., Coakley, R. D., Aleksandrov, A. A., Henderson, A. G., Zeman, K. L., Worthington, E. N., Gentzsch, M., Kreda, S. M., Cholon, D., et al. (2012) · The FASEB Journal · doi:10.1096/fj.11-192377 · Cited by 261
Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD
Donohue, J. F., Maleki-Yazdi, M. R., Kilbride, S., Mehta, R., Kalberg, C., & Church, A. (2013) · Respiratory Medicine · doi:10.1016/j.rmed.2013.06.001 · Cited by 259
Zheng, J.-P., Wen, F.-Q., Bai, C.-X., Wan, H.-Y., Kang, J., Chen, P., Yao, W.-Z., Ma, L.-J., Li, X., Raiteri, L., et al. (2014) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(13)70286-8 · Cited by 258
Chronic Obstructive Pulmonary Disease and Lung Cancer: New Molecular Insights
Adcock, I. M., Caramori, G., & Barnes, P. J. (2011) · Respiration · doi:10.1159/000324601 · Cited by 257
Guía Española de la EPOC (GesEPOC). Tratamiento farmacológico de la EPOC estable
Miravitlles, M., Soler-Cataluña, J. J., Calle, M., Molina, J., Almagro, P., Quintano, J. A., Riesco, J. A., Trigueros, J. A., Piñera, P., Simón, A., et al. (2012) · Archivos de Bronconeumología · doi:10.1016/j.arbres.2012.04.001 · Cited by 257
Mortality in COPD: Causes, Risk Factors, and Prevention
Berry, C. E., & Wise, R. A. (2010) · COPD: Journal of Chronic Obstructive Pulmonary Disease · doi:10.3109/15412555.2010.510160 · Cited by 257
Edwards, M. R., Bartlett, N. W., Hussell, T., Openshaw, P., & Johnston, S. L. (2012) · Nature Reviews Microbiology · doi:10.1038/nrmicro2801 · Cited by 205
Exacerbation rate, health status and mortality in COPD – a review of potential interventions
Seemungal, T. (2009) · International Journal of Chronic Obstructive Pulmonary Disease · doi:10.2147/copd.s3385 · Cited by 197
Structural insights into binding specificity, efficacy and bias of a β2AR partial agonist
Masureel, M., Zou, Y., Picard, L.-P., van der Westhuizen, E., Mahoney, J. P., Rodrigues, J. P. G. L. M., Mildorf, T. J., Dror, R. O., Shaw, D. E., Bouvier, M., et al. (2018) · Nature Chemical Biology · doi:10.1038/s41589-018-0145-x · Cited by 194
Unbalanced oxidant-induced DNA damage and repair in COPD: a link towards lung cancer
Caramori, G., Adcock, I. M., Casolari, P., Ito, K., Jazrawi, E., Tsaprouni, L., Villetti, G., Civelli, M., Carnini, C., Chung, K. F., et al. (2011) · Thorax · doi:10.1136/thx.2010.156448 · Cited by 187
Sussman, J. B., & Hayward, R. A. (2010) · BMJ · doi:10.1136/bmj.c2073 · Cited by 176
Chemokines in COPD: From Implication to Therapeutic Use
Henrot, P., Prevel, R., Berger, P., & Dupin, I. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20112785 · Cited by 131
Outcome measures in chronic obstructive pulmonary disease (COPD): strengths and limitations
Glaab, T., Vogelmeier, C., & Buhl, R. (2010) · Respiratory Research · doi:10.1186/1465-9921-11-79 · Cited by 130
“Strengths •All-cause mortality is the most robust and reliable outcome of clinical trials in COPD and is relatively easy to follow-up [4,83,84].”
BackgroundMethodAdcock, I. M., & Mumby, S. (2016) · Handbook of experimental pharmacology · doi:10.1007/164_2016_98 · Cited by 131
Gershon, A. S., Campitelli, M. A., Croxford, R., Stanbrook, M. B., To, T., Upshur, R., Stephenson, A. L., & Stukel, T. A. (2014) · JAMA · doi:10.1001/jama.2014.11432 · Cited by 121
Sample size calculation for comparing two negative binomial rates
Zhu, H., & Lakkis, H. (2014) · Statistics in Medicine · doi:10.1002/sim.5947 · Cited by 97
Jennings, J. H., Thavarajah, K., Mendez, M. P., Eichenhorn, M., Kvale, P., & Yessayan, L. (2015) · Chest · doi:10.1378/chest.14-1123 · Cited by 89
Number needed to treat in COPD: exacerbations versus pneumonias
Suissa, S. (2013) · Thorax · doi:10.1136/thoraxjnl-2012-202709 · Cited by 77
Translating statistical findings into plain English
Pocock, S. J., & Ware, J. H. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60499-2 · Cited by 67
Bewley, M. A., Belchamber, K. B. R., Chana, K. K., Budd, R. C., Donaldson, G., Wedzicha, J. A., Brightling, C. E., Kilty, I., Donnelly, L. E., Barnes, P. J., et al. (2016) · PLOS ONE · doi:10.1371/journal.pone.0163139 · Cited by 64
Geographic differences in clinical characteristics and management of COPD: The EPOCA study
Miravitlles, M. (2008) · International Journal of Chronic Obstructive Pulmonary Disease · doi:10.2147/copd.s4257 · Cited by 58
Bertoletti, L., Quenet, S., Laporte, S., Sahuquillo, J., Conget, F., Pedrajas, J., Martin, M., Casado, I., Riera-Mestre, A., Monreal, M., et al. (2013) · Respiratory Research · doi:10.1186/1465-9921-14-75 · Cited by 56
Viggers, H., Howden-Chapman, P., Ingham, T., Chapman, R., Pene, G., Davies, C., Currie, A., Pierse, N., Wilson, H., Zhang, J., et al. (2013) · BMC Public Health · doi:10.1186/1471-2458-13-176 · Cited by 29
The Number Needed to Treat: 25 Years of Trials and Tribulations in Clinical Research
Suissa, S. (2015) · Rambam Maimonides Medical Journal · doi:10.5041/rmmj.10218 · Cited by 28
Longitudinal Changes in Patient-reported Dyspnea in Patients with COPD
Mahler, D. A., Ward, J., Waterman, L. A., & Baird, J. C. (2012) · COPD: Journal of Chronic Obstructive Pulmonary Disease · doi:10.3109/15412555.2012.701678 · Cited by 27
Metadata
- Authors
- Calverley, P. M. A., Anderson, J. A., Celli, B., Ferguson, G. T., Jenkins, C., Jones, P. W., Yates, J. C., & Vestbo, J.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-02-22
- Volume
- 356
- Issue
- 8
- Pages
- 775-789
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2142724633
- Cited by
- 3,248
- References
- 26
- FWCI
- 222.11
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.